Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.495 +0.005 (+0.34%)
Streaming Delayed Price Updated: 1:55 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Allogene Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2025 ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Announces Participation in March Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise ↗
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy. 
Via Stocktwits
News headline image
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Friday's session: top gainers and losers ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
What's going on in today's session ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Friday's session: gap up and gap down stocks ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in February Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in December Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.